About Dr Min Hu

The main research aim is to improve the clinical outcome of transplantation by developing therapeutic strategies to achieve complete immunological tolerance to allografts. This would enable individuals with islet and kidney transplants to live drug-free following the initial period of tolerance induction. The specific aims of our research can be summarized as such: 1. To investigate the immune and genetics profile of kidney and islet transplant patients and identifying factors associated with good and poor outcomes. 2. To develop novel regimens for tolerance induction in small animal and pre-clinical models. 3) To develop immune therapeutic strategies to achieve peripheral and central transplant tolerance using haematopoietic chimerism and Tregs. 4) To generate allospecific Tregs for transplantation clinical trials.

I have a longstanding interest and expertise in transplantation research since 1999. I have contributed to the understanding in transplant tolerance and rejection, including clinical kidney, liver and islet transplanation, and also the induction of transplant tolerance in mouse models of heart, kidney, islet and skin transplants. The work has centred on the function of Tregs in protecting the allograft from rejection and limiting kidney disease, as well as development of chimerism in clinically relevant animal models and transplant recipients. My earlier research defined transplant tolerance in a liver transplant patient due to chimerism (N Engl J Med 2008), the role of T cell clones involved in kidney transplant rejection in paediatric patients (Am J Transplant 2004), and the TCR repertoire in human memory/naïve T cells in alloresponse (Blood 2004). More recently, I have been studying the alloresponse and immune profiling of islet transplant patients in a clinical trial (Am J Transplant 2013 and XXIII International Congress of TTS 2010). My Treg studies have focussed on the role of Tregs and translational Tregs therapy for kidney disease and transplant rejection in various animal models, including kidney transplants (Transplantation 2016, Am J Transplant 2013, Transpl Immunol, 2011, J Am Soc Nephrol. 2006, two papers 2012 , European J Immunol. 2012); human Treg expansion in vitro (Transplantation. 2014); human Treg expansion in vivo using humanised human-islet-transplant mouse-models (2014 World Transplant Congress); the development of therapeutic strategies to promote transplant tolerance in transplant mouse models(J Immunol. 2008, Cell Transplant. 2013, Transplant Immunology 2014); and induction of heart and skin transplant tolerance through chimerism (Transplantation 2015).

Dr. Min Hu, is a Senior Research Fellow with more than 40 publications (>22 in past 5 years).

Total career citations > 921

I am a senior Research Fellow and senior lecture at Centre for Transplant and Renal Research (CTRR), Westmead Institute for Medical Research (WIMR), University of Sydney (USyd). I am building an independent group within CTRR and has a longstanding interest and expertise in transplant immunology and renal disease. I have >40 publications (22 peer-reviewed journal articles in 5 past years). Majority of articles have been published in leading journals such as New England Journal of Medicine, Blood, American Journal of Transplantation, and American Society of Nephrology, Transplantation, Cell Transplantation, Kidney Int., and Journal of Immunology.

I was awarded an NHMRC Early Career Fellowship (2011-14), DVC Fellowship of USyd in 2015, 3 competitive grants from USyd (2 grants), and Diabetes Australia Research Program (2016) as CIA. I am an AI on the ARC/JDRF/CRN 2016-19 (CIA Prof. Philip O'Connell).

I am a committee member of Scientific Program and Education Committee of the Transplantation Society of Australia and New Zealand (TSANZ)(2015-present) and a member of ASI/NSW/ACT subcommittee (2012-present). I have organised and served on the organising committees of TSANZ (2016-17), Tregs Cell Therapy Workshop of TSANZ (2014), and monthly Westmead Hub Immunology Seminar. I was a convenor of the TSANZ Annual Scientific Meeting 2016.

I am passionate about training the next generation of clinician scientists and researchers. My aim is to recruit honours, Masters and PhD students from both science and medical background, and provide a good supervision for their career development.

I have supervised and supported 10 PhD, one Masters, 3 honours, 4 summer students, and 3 international visitor scholars. And many have received awards and/or travel grants and achieved ongoing successful careers in academic medicine or research.

Selected publications

1. Wu J, Hu M, Qian YW, Hawthorne WJ, Burns H, Liuwantara D, Alexander, S. Yi, and P. J. O'Connell. In Vivo Costimulation-blockade Induced Regulatory T Cells Demonstrate Dominant and Specific Tolerance to Porcine Islet-xenografts. Transplantation. 2017;101:1587-1599. Dr Hu is one of correspond authors and equal first author, and Wu's PhD co-supervisor.

2. Hu M, Wang YM, Wang Y, Zhang GY, Zhang G, Yi S, P J O'Connell, D C Harris, and SI Alexander. Regulatory T cells in kidney disease and transplantation. Regulatory T cells in kidney disease and transplantation. Kidney Int. 2016; 90:502-14;

3. Hu M, Kramer B, Zhang GY, Wang YM, Watson D, Howden B,McCowage G, Alexander IE, Gunning P, Alexander SI. Methyl-Guanine-Methyl-Transferase Transgenic Bone Marrow Transplantation Allows N,N-bis(2-chloroethyl)-Nitrosourea Driven Donor Mixed-Chimerism Without Graft-Versus-Host Disease, and With Donor-Specific Allograft Tolerance. Transplantation. 2015;99(12):2476-84.

4. Hu M, Wang C, Zhang GY, Saito M, Wang YM, Fernandez MA, Wang Y, Wu H, Hawthorne WJ, Jones C, O'Connell PJ, Sparwasser T, Bishop GA, Sharland AF, and Alexander SI. Infiltrating Foxp3(+) regulatory T cells from spontaneously tolerant kidney allografts demonstrate donor-specific tolerance. Am J Transplant. 2013;13(11):2819-30.

5. Polhill T, Zhang GY, Hu M, Sawyer A, Zhou JJ, Saito M, Webster KE, Wang Y, Wang Y, Grey ST, Sprent J, Harris DC, Alexander SI and Wang YM. IL-2/IL-2Ab complexes induce regulatory T cell expansion and protect against proteinuric CKD. J Am Soc Nephrol. 2012;23(8):1303-8.

6. Alexander SI, Smith N, Hu M, Verran D, Shun A, Dorney S, Smith A, Webster B, Shaw PJ, Lammi A, Stormon MO. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med. 2008;358(4):369-74.

7. Fletcher J*, HU Min* Berman Y, Collins F, Grigg J, McIver M, Juppner H, Alexander SI. Multicystic dysplastic kidney and variable phenotype in a family with a novel deletion mutation of PAX2. J Am Soc Nephrol. 2005 Sep;16(9):2754-61. (*DENOTES EQUAL CONTRIBUTION AND BOTH FIRST AUTHOR).